New advances transform the management of women with abnormal pap tests.
New advances in Papanicolaou test technology, human papillomavirus DNA testing, and revisions in the Bethesda terminology for cervical cytology have transformed the management of abnormal Pap tests. This approach has been validated by a recent randomized clinical trial, and in some instances can reduce the number of colposcopies by 50%.
Jin
Xian Wen
XW
Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA. jinx@ccf.org
Nielsen
Craig
C
Brainard
Jennifer
J
Yen-Lieberman
Belinda
B
D000328:Adult; D002986:Clinical Trials as Topic; D003127:Colposcopy / Q000706:statistics & numerical data*; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D006801:Humans; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000302:isolation & purification; D017410:Practice Guidelines as Topic; D012680:Sensitivity and Specificity; D009626:Terminology as Topic; D014626:Vaginal Smears / Q000145:classification* / Q000379:methods
D004279:DNA, Viral